

Christopher J Edwards

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6335599/publications.pdf>

Version: 2024-02-01

58
papers

1,417
citations

471509

17
h-index

345221

36
g-index

62
all docs

62
docs citations

62
times ranked

2096
citing authors

#	ARTICLE	IF	CITATIONS
1	Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3). <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1065-1073.	0.9	225
2	Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren's Syndrome. <i>Arthritis and Rheumatology</i> , 2017, 69, 1440-1450.	5.6	194
3	Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. <i>Lancet, The</i> , 2021, 397, 305-317.	13.7	145
4	Trends and determinants of length of stay and hospital reimbursement following knee and hip replacement: evidence from linked primary care and NHS hospital records from 1997 to 2014. <i>BMJ Open</i> , 2018, 8, e019146.	1.9	97
5	Functionally distinct ERAP1 allotype combinations distinguish individuals with Ankylosing Spondylitis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 17594-17599.	7.1	90
6	Apremilast monotherapy in DMARD-naïve psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial. <i>Rheumatology</i> , 2018, 57, 1253-1263.	1.9	72
7	Dosing down with biologic therapies: a systematic review and clinicians' perspective. <i>Rheumatology</i> , 2017, 56, 1847-1856.	1.9	59
8	Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis. <i>Arthritis Research and Therapy</i> , 2019, 21, 118.	3.5	55
9	Inflammation and dementia: Using rheumatoid arthritis as a model to develop treatments?. <i>Autoimmunity Reviews</i> , 2018, 17, 919-925.	5.8	40
10	Patient-reported outcomes and safety in patients undergoing synovial biopsy: comparison of ultrasound-guided needle biopsy, ultrasound-guided portal and forceps and arthroscopic-guided synovial biopsy techniques in five centres across Europe. <i>RMD Open</i> , 2018, 4, e000799.	3.8	31
11	Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1-3 studies. <i>RMD Open</i> , 2018, 4, e000669.	3.8	31
12	Defining inflammatory musculoskeletal manifestations in systemic lupus erythematosus. <i>Rheumatology</i> , 2019, 58, 304-312.	1.9	28
13	Clinical trials of new drugs for the treatment of rheumatoid arthritis: focus on early disease. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1268-1271.	0.9	26
14	Does Combined Clinical and Ultrasound Assessment Allow Selection of Individuals With Rheumatoid Arthritis for Sustained Reduction of Anti-Tumor Necrosis Factor Therapy?. <i>Arthritis Care and Research</i> , 2015, 67, 746-753.	3.4	24
15	Association between NICE guidance on biologic therapies with rates of hip and knee replacement among rheumatoid arthritis patients in England and Wales: An interrupted time-series analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 47, 605-610.	3.4	21
16	Lupus, vaccinations and COVID-19: What we know now. <i>Lupus</i> , 2021, 30, 1541-1552.	1.6	21
17	The effectiveness of a real life dose reduction strategy for tumour necrosis factor inhibitors in ankylosing spondylitis and psoriatic arthritis. <i>Rheumatology</i> , 2016, 55, 1837-1842.	1.9	19
18	The impact of rheumatoid arthritis on the risk of adverse events following joint replacement: a real-world cohort study. <i>Clinical Epidemiology</i> , 2018, Volume 10, 697-704.	3.0	18

#	ARTICLE	IF	CITATIONS
19	Switching to biosimilars: current perspectives in immune-mediated inflammatory diseases. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 1001-1014.	3.1	18
20	Tapering versus steady-state methotrexate in combination with tocilizumab for rheumatoid arthritis: a randomized, double-blind trial. <i>Rheumatology</i> , 2018, 57, 84-91.	1.9	17
21	What is the added value of ultrasound joint examination for monitoring synovitis in rheumatoid arthritis and can it be used to guide treatment decisions? A systematic review and cost-effectiveness analysis. <i>Health Technology Assessment</i> , 2018, 22, 1-258.	2.8	17
22	Ultrasound to identify systemic lupus erythematosus patients with musculoskeletal symptoms who respond best to therapy: the US Evaluation For musculoskeletal Lupus longitudinal multicentre study. <i>Rheumatology</i> , 2021, 60, 5194-5204.	1.9	16
23	Clinical management of Lupus patients during the COVID-19 pandemic. <i>Lupus</i> , 2020, 29, 1661-1672.	1.6	15
24	Impact of TNF inhibitor therapy on joint replacement rates in rheumatoid arthritis: a matched cohort analysis of BSRBR-RA UK registry data. <i>Rheumatology</i> , 2019, 58, 1168-1175.	1.9	13
25	Descriptive epidemiology of hip and knee replacement in rheumatoid arthritis: An analysis of UK electronic medical records. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 237-244.	3.4	12
26	2019 EULAR points to consider for the assessment of competences in rheumatology specialty training. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 65-70.	0.9	12
27	Can the publication of guidelines change the management of early rheumatoid arthritis? An interrupted time series analysis from the United Kingdom. <i>Rheumatology</i> , 2015, 54, kev268.	1.9	11
28	The effect of rheumatoid arthritis on patient-reported outcomes following knee and hip replacement: evidence from routinely collected data. <i>Rheumatology</i> , 2019, 58, 1016-1024.	1.9	11
29	Predicting disease progression and poor outcomes in patients with moderately active rheumatoid arthritis: a systematic review. <i>Rheumatology Advances in Practice</i> , 2019, 3, rkz002.	0.7	9
30	Switching to biosimilar infliximab: real world data in patients with severe inflammatory arthritis. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 171-172.	0.8	9
31	The reliability of a novel magnetic resonance imaging-based tool for the evaluation of forefoot bursae in patients with rheumatoid arthritis: the FFB score. <i>Rheumatology</i> , 2014, 53, 2014-2017.	1.9	6
32	Are there dangers in biologic dose reduction strategies?. <i>Autoimmunity Reviews</i> , 2016, 15, 742-746.	5.8	6
33	A Matching-Adjusted Indirect Comparison of Upadacitinib Versus Tofacitinib in Adults with Moderate-to-Severe Rheumatoid Arthritis. <i>Rheumatology and Therapy</i> , 2021, 8, 167-181.	2.3	6
34	Apremilast monotherapy for long-term treatment of active psoriatic arthritis in DMARD-naïve patients. <i>Rheumatology</i> , 2022, 61, 1035-1043.	1.9	6
35	Raising the quality of rheumatology management recommendations: lessons from the EULAR process 10 years after provision of standard operating procedures. <i>Rheumatology</i> , 2015, 54, 1392-1396.	1.9	5
36	Both rare and common ERAP1 allotypes have distinct functionality defined by polymorphic context and are important in AS association. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E1575-E1576.	7.1	5

#	ARTICLE	IF	CITATIONS
37	Efficacy and Safety of Etanercept in Elderly Patients with Rheumatoid Arthritis: A Post-Hoc Analysis of Randomized Controlled Trials. <i>Drugs and Aging</i> , 2019, 36, 853-862.	2.7	5
38	Characteristics of hand involvement in a comparative study of two early <sc>RA</sc> cohorts from the <sc>UK</sc> and <sc>C</sc>hina. <i>International Journal of Rheumatic Diseases</i> , 2017, 20, 1426-1436.	1.9	3
39	Comparison of Responsiveness of British Isles Lupus Assessment Group 2004 Index, Systemic Lupus Erythematosus Disease Activity Index 2000, and British Isles Lupus Assessment Group 2004 Systems Tally. <i>Arthritis Care and Research</i> , 2022, 74, 1623-1630.	3.4	3
40	O10â€fCharacteristics of patients who discontinued baricitinib treatment within 12 months and reasons for discontinuation: real-world data. <i>Rheumatology</i> , 2021, 60, .	1.9	3
41	An Analysis of Real-World Data on the Safety of Etanercept in Older Patients with Rheumatoid Arthritis. <i>Drugs and Aging</i> , 2020, 37, 35-41.	2.7	2
42	Outcomes of children born to mothers with systemic lupus erythematosus exposed to hydroxychloroquine or azathioprine. <i>Rheumatology</i> , 0, , .	1.9	2
43	Reply to Robinson and Brown: It is the combination of ERAP1 allotypes that identifies individuals with Ankylosing Spondylitis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E1817-E1817.	7.1	1
44	E062â€fBaseline characteristics of patients with rheumatoid arthritis starting the janus kinase inhibitor baricitinib: real-life observation study. <i>Rheumatology</i> , 2019, 58, .	1.9	1
45	O33â€fBaricitinib in the BSRBR-RA registry: characteristics and status of patients at first follow-up. <i>Rheumatology</i> , 2021, 60, .	1.9	1
46	Anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies: incidence using different testing criteria, and case series. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 298-303.	0.8	1
47	Are guidelines good value for money?: Fig. 1. <i>Rheumatology</i> , 2015, 54, kev308.	1.9	0
48	Phase I studies: the role of publicly funded academic-healthcare partnerships. <i>BMJ, The</i> , 2015, 351, h3889.	6.0	0
49	125â€fAn Exploration of the Characteristics of Early Rheumatoid Arthritis Hand Involvement Among Different Gender, Age and Hand-Dominance in a Chinese Population. <i>Rheumatology</i> , 2016, , .	1.9	0
50	190.â€fRHEUMATOID ARTHRITIS, A STUDY OF CONTINUOUS MONITORING OF PHYSICAL ACTIVITY USING SMARTPHONES. <i>Rheumatology</i> , 2017, 56, .	1.9	0
51	242â€fBaseline characteristics of patients with lupus nephritis requiring rituximab therapy: results from the British Isles Lupus Assessment Group Biologics Register (BILAG-BR). <i>Rheumatology</i> , 2019, 58, .	1.9	0
52	Hydroxychloroquine and coronavirus disease 19. <i>Lupus</i> , 2020, 29, 669-670.	1.6	0
53	O23â€fIxekizumab (IXE) vs. adalimumab (ADA) for the treatment of PSA: 52-week efficacy and safety outcomes. <i>Rheumatology</i> , 2020, 59, .	1.9	0
54	TNF inhibitors for the prevention of Alzheimerâ€™s disease: Preliminary findings from the rheumatoid arthritis medication and memory study (RESIST). <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0

#	ARTICLE	IF	CITATIONS
55	Anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies: incidence using different testing criteria, and case series.. Clinical and Experimental Rheumatology, 2022, 40, 298-303.	0.8	0
56	P244â€fThe use of anti-malarial therapy in UK Rheumatology practice. A UK-based pilot survey for the BILAG group. Rheumatology, 2022, 61, .	1.9	0
57	P246â€fRevision to musculoskeletal domain of BILAG-2004 index to incorporate ultrasound findings. Rheumatology, 2022, 61, .	1.9	0
58	The BILAG-2004 index is associated with development of new damage in SLE. Rheumatology, 0, , .	1.9	0